Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday September 30, 2009

DrStockPick.com Stock Report!

COV, PWRM, MSFT, CSRH, NKE, CVAT, ABT

**************************************************************

COV, Covidien plc

COV engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings worldwide. The company operates through four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products, and Medical Supplies.

COV said Wednesday it received Food and Drug Administration clearance for its new endotracheal tube, a device that helps patients breathe.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday September 28, 2009

DrStockPick.com Stock Report!

XRX, PWRM, ABT, CSRH, CMCSA, CVAT, FMCN

**************************************************************

XRX, Xerox Corp.

XRX engages in the development, manufacture, marketing, servicing, and financing of document equipment, software, solutions, and services worldwide.

XRX said Monday it will buy Affiliated Computer Services Inc. for $6.4 billion in cash and stock to create a $22 billion business that combines XRX’s copiers, printers and document management services with the “business process outsourcing” of Dallas-based ACS., joining the expensive race among technology companies to broaden their offerings.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in

...

Yesterday, AstraZeneca Plc (AZN) announced that Crestor, its cholesterol-lowering drug (statin) reduced the risk of heart attacks, strokes, artery-clearing procedures and death in elderly patients. The results from the JUPITER study (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin), showed that Crestor 20mg reduced major cardiovascular events. The administration of the drug to a sub-set of 5,695 patients aged 70 years or above reduced the risk of cardiovascular events by 39% compared to placebo. The study also revealed that Crestor reduced the risk of heart attack as well as stroke by 45% each in 17,802 patients (the total population of the study). The results were presented at the European Society of Cardiology (ESC) meeting in Barcelona, Spain. Results from the randomized, double-blind, placebo-controlled study were initially presented in November 2008. We feel that the analysis from the JUPITER ...

Amarin Corporation plc announced that it had secured financing of $3.0 million in the form of convertible bridge loan notes sold to several institutional investors. The financing consists of a short-term note and warrants, and will allow the company to operate through the end of September 2009.

The notes pay interest at a rate of 8%, mature on September 30, 2009, and are convertible at the option of the holder into the company’s American Depositary Shares. The warrants are for five years and are also convertible into American Depositary Shares based on a price to be determined in the future.

Amarin Corporation plc is attempting to place more permanent financing and has signed a non-binding agreement with several investors for up to $55 million in financing. The company has commitments for a little more than 50% of this amount.

Amarin Corporation plc is a biotechnology company that is

...

We are pleased with Lexicon Pharma (LXRX) receiving the orphan drug designation for LX1032 from the Committee for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA). The drug is currently in phase II development for the treatment of gastrointestinal symptoms associated with carcinoid syndrome.

LX1032 is the first drug candidate for which Lexicon has received the orphan drug status from the EMEA. It already has fast track designation from the US FDA. With this status, the company will get many incentives in the form of regulatory assistance, reduced regulatory fees associated with marketing approval application and assistance with clinical trial design. A major advantage that comes with orphan drug status is that the product will enjoy ten years of marketing exclusivity once it is approved.

Apart from LX1032, Lexicon has other candidates in various stages of development including LX1031, LX2931 and LX6171. Additionally, the company has other candidates in

...

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following additional categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage pivotal Phase 3 clinical trial results which are designed to support a filing for FDA approval.

On 6/4/09, Abbott Labs [ABT: 45.42, +0.86 (+1.93%)] and AstraZeneca [AZN: 43.34, +1.70 (+4.08%)] announced that the companies have submitted a New Drug Application (NDA) to the FDA for an investigational compound to treat mixed dyslipidemia, a combination of two

...

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete response rulings by the agency which require more information before an approval can be granted.

Clinical Data [CLDA: 11.83, -0.23 (-1.91%)] announced positive top-line results on 6/2/09 from the second of two Phase 3 trials of its investigational compound, vilazodone, for the treatment of major depressive disorder (MDD). In the study, vilazodone achieved statistically significant results on the primary

...